Selatogrel clinical trials
Also written ACT-246475.
Its developmentBy Viatris and Idorsia Pharmaceuticals, step by step11 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses selatogrel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the selatogrel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 11 · Other 0
Viatris Innovation GmbH (10) · Idorsia Pharmaceuticals Ltd. (1)
Often tested with
Tested in the same studies.
Clopidogrel (1) · Prasugrel (1) · Ticagrelor (1) · ACT-281959 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test selatogrel, phase 3 first.
- Jul 2027Selatogrel Outcome Study in Suspected Acute Myocardial InfarctionPhase 3 · Viatris Innovation GmbH
Studies
Open first, then newest update. How each study uses selatogrel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Selatogrel Outcome Study in Suspected Acute Myocardial InfarctionEnrolling by invitationPhase 3Viatris Innovation GmbHNCT04957719Written as Selatogrel
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary SyndromeCompletedPhase 1Viatris Innovation GmbHNCT07615868Written as Selatogrel
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery DiseaseCompletedPhase 2Viatris Innovation GmbHNCT03384966Written as Selatogrel
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart AttackCompletedPhase 2Viatris Innovation GmbHNCT03487445Written as Selatogrel 8 mg
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy ParticipantsCompletedPhase 1Viatris Innovation GmbHNCT07133191Written as Selatogrel
- The Effect of Reduced Liver Function on Selatogrel PharmacokineticsCompletedPhase 1Viatris Innovation GmbHNCT04406896Written as Selatogrel
- A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy SubjectsCompletedPhase 1Viatris Innovation GmbHNCT04557280Written as Selatogrel
- A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy SubjectsCompletedPhase 1Viatris Innovation GmbHNCT03814200Written as ACT-246475
- A Study to Evaluate ACT-246475 Fate in Healthy Male SubjectsCompletedPhase 1Viatris Innovation GmbHNCT03593278Written as ACT-246475
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsCompletedPhase 1Viatris Innovation GmbHNCT03430661Written as ACT-246475
- Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT01954615Written as ACT-246475 (Group G dose to be defined)
Codes
What other systems call selatogrel · ClinicalTrials.gg INT000311
- MeSH (NLM) C000601315selatogrelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6DPK7O4PR7SELATOGRELConfirmed FDA, NLM, Wikidata
- Wikidata Q76754380selatogrelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166930SelatogrelOne source FDA
- DrugBank DB15163One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601315 | selatogrel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6DPK7O4PR7 | SELATOGREL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76754380 | selatogrel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166930 | Selatogrel | One source FDA |
| DrugBank | DB15163 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.